Utilization, Cost, and Outcome of Branded vs Compounded 17-Alpha Hydroxyprogesterone Caproate in Prevention of Preterm Birth

Inbar Fried; Andrew L Beam; Isaac S Kohane; Nathan P Palmer

doi:10.1001/jamainternmed.2017.5017

Utilization, Cost, and Outcome of Branded vs Compounded 17-Alpha Hydroxyprogesterone Caproate in Prevention of Preterm Birth

JAMA Intern Med. 2017 Nov 1;177(11):1689-1690. doi: 10.1001/jamainternmed.2017.5017.

Authors

Inbar Fried¹, Andrew L Beam¹, Isaac S Kohane¹, Nathan P Palmer¹

Affiliation

¹ Department of Biomedical Informatics, Harvard Medical School, Boston Massachusetts.

Abstract

This study compares the utilization, cost, and outcome data from an insurance claims database to determine the difference in treatment efficacy between the branded and compounded versions of 17-alpha hydroxyprogesterone caproate.

MeSH terms

17 alpha-Hydroxyprogesterone Caproate / administration & dosage*
17 alpha-Hydroxyprogesterone Caproate / economics
Adult
Databases, Factual
Drug Costs / trends*
Drug Utilization / economics
Drug Utilization / trends*
Female
Humans
Infant, Newborn
Pregnancy
Premature Birth / epidemiology
Premature Birth / prevention & control*
Progestins / administration & dosage*
Progestins / economics

Substances

Progestins
17 alpha-Hydroxyprogesterone Caproate